Ardsley Advisory Partners’s Trinity Biotech TRIB Stock Holding History

Ardsley Advisory Partners’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-10,500	Closed	-$601K	–	188
2015 Q3	$601K	Hold	10,500	–	–	0.15%	79
2015 Q2	$948K	Buy	10,500 +3,500	+50%	+$303K	0.12%	79
2015 Q1	$674K	Buy	7,000 +2,000	+40%	+$185K	0.09%	105
2014 Q4	$438K	Buy	5,000 +1,000	+25%	+$86.2K	0.07%	130
2014 Q3	$365K	Hold	4,000	–	–	0.05%	140
2014 Q2	$461K	Buy	4,000 +1,500	+60%	+$178K	0.06%	166
2014 Q1	$303K	Buy	2,500 +500	+25%	+$65.6K	0.05%	183
2013 Q4	$251K	Sell	2,000 -500	-20%	-$60K	0.03%	133
2013 Q3	$272K	Sell	2,500 -1,500	-38%	-$146K	0.06%	105
2013 Q2	$337K	Buy	+4,000	New	+$332K	0.07%	96

Other funds holding TRIB

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

AAM

ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Ardsley Advisory Partners's TRIB Position: Q4 2015 in Review

Ardsley Advisory Partners sold out of Trinity Biotech (TRIB) in Q4 2015, closing a stake of 10,500 shares — an estimated $601K sold.

Ardsley Advisory Partners first reported a position in TRIB in Q2 2013 and held it in 10 quarters. The position peaked at $948K in Q2 2015. 82 funds tracked by Wall St. Rank hold TRIB as of Q4 2015.

Ardsley Advisory Partners reported no remaining Trinity Biotech position as of Q4 2015 after selling out during the quarter.
Ardsley Advisory Partners sold 10,500 Trinity Biotech shares in Q4 2015, an estimated $601K.
Ardsley Advisory Partners first reported a position in Trinity Biotech in Q2 2013 and held it in 10 quarters.
Ardsley Advisory Partners's Trinity Biotech position peaked at $948K in Q2 2015.
82 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2015.

Based on Ardsley Advisory Partners's 13F filing for Q4 2015, filed 16 Feb 2016.